Cargando…
Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
Glioblastoma multiforme (GBM) is the most common and malignant brain tumor, and almost half of the patients carrying EGFR-driven tumor with PTEN deficiency are resistant to EGFR-targeted therapy. EGFR amplification and/or mutation is reported in various epithelial tumors. This series of studies aime...
Autores principales: | He, Kunyan, Wang, Guang-Xing, Zhao, Li-Nan, Cui, Xiao-Fang, Su, Xian-Bin, Shi, Yi, Xie, Tian-Pei, Hou, Shang-Wei, Han, Ze-Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672866/ https://www.ncbi.nlm.nih.gov/pubmed/34925034 http://dx.doi.org/10.3389/fphar.2021.775602 |
Ejemplares similares
-
Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Li, Xiaohe, et al.
Publicado: (2019) -
Preclinical study of cinobufagin as a promising anti-colorectal cancer agent
por: Lu, Xing-sheng, et al.
Publicado: (2016) -
Spatial Lipidomics Reveals Anticancer Mechanisms of Bufalin in Combination with Cinobufagin in Tumor-Bearing Mice
por: Zhang, Jinghui, et al.
Publicado: (2021) -
Pharmacological Effects of Cinobufagin
por: Zhang, Hao, et al.
Publicado: (2023) -
Cinobufagin alleviates lipopolysaccharide-induced acute lung injury by regulating autophagy through activation of the p53/mTOR pathway
por: Wang, Cheng, et al.
Publicado: (2022)